Geminin overexpression-dependent recruitment and crosstalk with mesenchymal stem cells enhance aggressiveness in triple negative breast cancers

Abstract

Resident mesenchymal stem cells (MSCs) promote cancer progression. However, pathways and mechanisms involved in recruiting MSCs into breast tumors remain largely undefined. Here we show that geminin-dependent acetylation releases HMGB1 from the chromatin to the cytoplasm and extracellular space. Extracellular acetylated HMGB1 (Ac-HMGB1) promotes geminin overexpressing (GemOE) cells survival by binding to RAGE and activating NF-κB signaling. Extracellular Ac-HMGB1 also triggers expression and activation of RAGE in the non-expressing MSCs. RAGE activation induces expression of CXCR4 in MSCs and directional migration towards SDF1 (aka CXCL12)-expressing GemOE cells in vitro and in vivo. These effects augmented by the necrotic and hypoxic environment in GemOE tumors, especially within their cores. Reciprocal interactions between newly recruited MSCs and GemOE tumor cells elevate tumor-initiating (TIC), basal and epithelial-to-mesenchymal transition (EMT) traits and enhance aggressiveness in vitro and in vivo in GemOE tumor cells. Indeed, faster, larger and more aggressive tumors develop when GemOE cells are co-injected with MSCs in orthotopic breast tumor model. Concurrently, inhibiting c-Abl (and thus geminin function), RAGE or CXCR4 prevented MSCs recruitment to GemOE cells in vitro and in vivo, and decreased the TIC, basal and EMT phenotypes in these tumor cells. Accordingly, we propose that GemOE tumor cells present within tumor cores represent metastatic precursors, and suppressing the GemOE→HMGB1/RAGE→SDF1/CXCR4 signaling circuit could be a valid target for therapies to inhibit GemOE tumors and their metastases.

Emerging Trends in Ocular Drug Delivery: A Review on Recent Updates

“…Large experimental groups of animals are needed considering the sample volume and number of samples need to be taken for estimation of peak concentration in tissue and time to achieve maximum concentration in tissue. As patient acceptance is less regarding multiple drug dosages, sustained release formulations are being developed [26]. Several studies are already available where sustained release dosage forms are developed [13].…”

Enhanced Bioavailability and Anticancer Activity of Vitamin Analogs

“…Tumor metastasis leads to the death of patient due to poor response to the treatment. Metastasis greatly changes the genotype of the cancer cells due to multiple mutations leading to more aggressive form [37][38][39][40][41]. It is not easy to track the metastatic cells during the process and further making it difficult to target.…”

A Brief Journey of Tocotrienols as Anticancer Agents

“…Cancer is the biggest threat to mankind due to its aggressive, uncontrollable growth and metastatic properties [22][23][24][25][26]. The first ever anticancer activity of tocotrienols was found by Komiyama et al The research group developed tumor model in mice by injecting cells i.p.…”